AU722985B2 - Compounds and methods for modulating cell adhesion - Google Patents

Compounds and methods for modulating cell adhesion Download PDF

Info

Publication number
AU722985B2
AU722985B2 AU33322/97A AU3332297A AU722985B2 AU 722985 B2 AU722985 B2 AU 722985B2 AU 33322/97 A AU33322/97 A AU 33322/97A AU 3332297 A AU3332297 A AU 3332297A AU 722985 B2 AU722985 B2 AU 722985B2
Authority
AU
Australia
Prior art keywords
cyclic peptide
cadherin
mammal
cells
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU33322/97A
Other languages
English (en)
Other versions
AU3332297A (en
Inventor
Orest W. Blaschuk
Barbara Joan Gour
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
McGill University
Original Assignee
McGill University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by McGill University filed Critical McGill University
Publication of AU3332297A publication Critical patent/AU3332297A/en
Application granted granted Critical
Publication of AU722985B2 publication Critical patent/AU722985B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU33322/97A 1996-07-12 1997-07-11 Compounds and methods for modulating cell adhesion Ceased AU722985B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2161296P 1996-07-12 1996-07-12
US60/021612 1996-07-12
PCT/CA1997/000489 WO1998002452A2 (en) 1996-07-12 1997-07-11 Compounds and methods for modulating cell adhesion

Publications (2)

Publication Number Publication Date
AU3332297A AU3332297A (en) 1998-02-09
AU722985B2 true AU722985B2 (en) 2000-08-17

Family

ID=21805187

Family Applications (1)

Application Number Title Priority Date Filing Date
AU33322/97A Ceased AU722985B2 (en) 1996-07-12 1997-07-11 Compounds and methods for modulating cell adhesion

Country Status (8)

Country Link
US (3) US6031072A (enExample)
EP (1) EP0937103B1 (enExample)
JP (1) JP2001500475A (enExample)
AU (1) AU722985B2 (enExample)
CA (1) CA2259966A1 (enExample)
DE (1) DE69738326T2 (enExample)
ES (1) ES2297861T3 (enExample)
WO (1) WO1998002452A2 (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6169071B1 (en) 1996-07-12 2001-01-02 Mcgill University Compounds and methods for modulating cell adhesion
US6346512B1 (en) 1996-07-12 2002-02-12 Mcgill University Compounds and methods for modulating cell adhesion
US6207639B1 (en) 1996-07-12 2001-03-27 Mcgill University Compounds and methods for modulating neurite outgrowth
US6031072A (en) 1996-07-12 2000-02-29 Mcgill University Compounds and methods for modulating cell adhesion
US6333307B1 (en) 1996-07-12 2001-12-25 Mcgill University Compounds and method for modulating neurite outgrowth
US6562786B1 (en) 1996-07-12 2003-05-13 Mcgill University Compounds and methods for modulating apoptosis
US6610821B1 (en) * 1996-07-12 2003-08-26 Mcgill University Compounds and methods for modulating endothelial cell adhesion
US6417325B1 (en) 1996-07-12 2002-07-09 Mcgill University Compounds and methods for cancer therapy
US20020168761A1 (en) * 2000-01-24 2002-11-14 Gour Barbara J. Peptidomimetic modulators of cell adhesion
US20040006011A1 (en) * 1996-07-12 2004-01-08 Gour Barbara J. Peptidomimetic modulators of cell adhesion
US7122623B2 (en) 1996-07-12 2006-10-17 Adherex Technologies, Inc. Compounds and methods for modulating cell adhesion
US6465427B1 (en) 1996-07-12 2002-10-15 Mcgill University Compounds and methods for modulating cell adhesion
US6551994B1 (en) * 1997-04-10 2003-04-22 Mcgill University Compounds and methods for inhibiting the interaction between α-catenin and β-catenin
US6638911B1 (en) * 1998-05-05 2003-10-28 Adherex Technologies Inc. Compounds and methods for modulating desmosomal cadherin-mediated functions
US20050203025A1 (en) * 1998-05-05 2005-09-15 Adherex Technologies, Inc. Compounds and methods for modulating nonclassical cadherin-mediated functions
US6472367B1 (en) 1998-05-05 2002-10-29 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin mediated cell adhesion
US7481999B2 (en) * 1998-05-05 2009-01-27 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin-mediated function
US6680175B2 (en) 1998-05-05 2004-01-20 Adherex Technologies, Inc. Methods for diagnosing and evaluating cancer
US6433149B1 (en) 1998-05-05 2002-08-13 Adherex Technologies, Inc. Compounds and methods for inhibiting cancer metastasis
CA2337794A1 (en) 1998-07-02 2000-01-13 Jennifer D. Tousignant Transgene expression in polarized cells
US6277824B1 (en) * 1998-07-10 2001-08-21 Adherex Technologies Compounds and methods for modulating adhesion molecule function
AU4417000A (en) * 1999-04-15 2000-11-02 Glaxo Group Limited Novel pharmaceutical composition suitable for gene therapy
US20040254099A1 (en) * 1999-04-21 2004-12-16 Adherex Technologies, Inc. Compounds and methods for modulating beta-catenin mediated gene expression
US6303576B1 (en) * 1999-04-21 2001-10-16 Adherex Technologies Inc. Compounds and methods for modulating β-catenin mediated gene expression
US6391855B1 (en) * 1999-06-02 2002-05-21 Adherex Technologies, Inc. Compounds and methods for modulating junctional adhesion molecule-mediated functions
US6787136B1 (en) 1999-09-03 2004-09-07 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
WO2002034880A2 (en) * 2000-10-23 2002-05-02 University Of Kansas Cadherin peptides for drug delivery and inhibition of tumor metastasis/invasion
US6815426B2 (en) * 2001-02-16 2004-11-09 E. I. Du Pont De Nemours And Company Angiogenesis-inhibitory tripeptides, compositions and their methods of use
US20020192206A1 (en) * 2001-05-05 2002-12-19 Kozarov Emil V. Methods and compositions for angioproliferative disorder treatment
US20030105025A1 (en) * 2001-10-31 2003-06-05 Fortuna Haviv Tri-and tetrapeptides having antiangiogenic activity
US7175990B2 (en) * 2002-02-26 2007-02-13 The Regents Of The University Of California Method of determining endometrial receptivity
EP1560850A2 (en) 2002-11-14 2005-08-10 Adherex Technologies, Inc. Compounds and methods for modulating desmosomal and atypical cadherin-mediated cell adhesion
WO2004044000A2 (en) * 2002-11-14 2004-05-27 Adherex Technologies, Inc. Compounds and methods for modulating functions of classical cadherins
US7196061B2 (en) 2003-09-10 2007-03-27 Wyeth Compounds that modulate neuronal growth and their uses
WO2005039506A2 (en) * 2003-10-24 2005-05-06 Exelixis, Inc. P70s6 kinase modulators and method of use
CN1933832A (zh) * 2004-03-08 2007-03-21 惠氏公司 离子通道调节剂
US7169756B2 (en) * 2004-04-16 2007-01-30 Mcmaster University Streptogramin antibiotics
KR101203328B1 (ko) * 2005-04-26 2012-11-20 화이자 인코포레이티드 Ｐ-카드헤린 항체
US7691839B2 (en) 2005-09-28 2010-04-06 Biovascular, Inc. Methods and compositions for blocking platelet and cell adhesion, cell migration and inflammation
US20110034396A1 (en) * 2005-09-28 2011-02-10 Biovascular, Inc. Methods and compositions for inhibiting cell migration and treatment of inflammatory conditions
JP2009538282A (ja) * 2006-05-15 2009-11-05 バイオジェン・アイデック・エムエイ・インコーポレイテッド 乏突起膠細胞の生存を促進させるためのＮｏｇｏ受容体−１（ＮｇＲ１）アンタゴニストの使用
US20080194467A1 (en) * 2006-09-27 2008-08-14 Adherex Technologies, Inc. Cancer treatment methods using cadherin antagonists in combination with anticancer agents
EP2091552A4 (en) 2006-11-15 2010-01-06 Dana Farber Cancer Inst Inc STABILIZED MAML-PEPTIDES AND ITS USES
US20090291967A1 (en) * 2008-03-05 2009-11-26 Adherex Technologies, Inc. Small molecule modulators of cell adhesion
US9599603B2 (en) * 2008-07-16 2017-03-21 Case Western Reserve University Methods and compositions for modulating adhesion and migration of cadherin expressing cells
EP2376100B1 (en) 2009-01-14 2017-10-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US8680150B2 (en) 2009-05-28 2014-03-25 Ligand Pharmaceuticals, Inc. Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors
WO2011038049A1 (en) * 2009-09-22 2011-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US8877188B2 (en) 2010-05-04 2014-11-04 The Brigham And Women's Hospital, Inc. Detection and treatment of non-dermal fibrosis
FR2980741B1 (fr) 2011-09-30 2014-03-14 Saint Gobain Procede d'assemblage par collage d'un vitrage sur un support avec interposition d'une cale d'ecartement, vitrage muni d'une cale d'ecartement, cale, cordon profile et ensemble de cales.
US8633158B1 (en) 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
AU2014268524A1 (en) 2013-05-24 2015-12-03 Tarix Pharmaceuticals Ltd. Angiotensin peptides in treating Marfan Syndrome and related disorders
US9133241B2 (en) 2013-10-11 2015-09-15 Tarix Pharmaceuticals Ltd. Peptide compositions
WO2015054006A2 (en) 2013-10-11 2015-04-16 Tarix Pharmaceuticals Ltd. Novel peptide compositions
WO2015077763A1 (en) 2013-11-25 2015-05-28 Stc.Unm Cxcr antagonistic peptides and uses thereof
US9333233B2 (en) 2014-02-25 2016-05-10 Tarix Pharmaceuticals Ltd. Methods and compositions for the delayed treatment of stroke
EP3164417A1 (en) 2014-07-01 2017-05-10 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
WO2016100301A1 (en) 2014-12-15 2016-06-23 The Brigham And Women's Hospital, Inc. Use of cadherin-11 antagonists to treat obesity-associated conditions and other metabolic disorders
GB2538947A (en) 2014-12-19 2016-12-07 Neuro-Bio Ltd Cancer
WO2016097753A1 (en) * 2014-12-19 2016-06-23 Neuro-Bio Ltd Cyclic acetylcholinesterase c-terminal peptide in the treatment or prevention of cancer or metastasis
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
MA43230A (fr) 2015-10-14 2021-04-14 Tarix Pharmaceuticals Ltd Méthodes et compositions pour le traitement d'une épidermolyse bulleuse
KR102167755B1 (ko) * 2018-05-23 2020-10-19 주식회사 큐어바이오 단편화된 grs 폴리펩타이드, 이의 변이체 및 이들의 용도
WO2020257745A1 (en) * 2019-06-21 2020-12-24 University Of Kansas Compositions and methods useful in treating brain diseases
WO2021183863A1 (en) 2020-03-13 2021-09-16 Constant Therapeutics Llc Methods and compositions for treatment of coronavirus infection
KR20220061018A (ko) * 2020-11-05 2022-05-12 한국생명공학연구원 항염 및 조직 재생작용을 갖는 신규 펩타이드
CN116535281B (zh) * 2022-01-25 2025-06-24 中国科学院大连化学物理研究所 一种手性环状单萜衍生物及其合成方法
CN116535406B (zh) * 2022-01-25 2025-06-24 中国科学院大连化学物理研究所 一种多萜衍生物的对映选择性合成方法及多萜衍生物
WO2025122594A1 (en) 2023-12-04 2025-06-12 Constant Therapeutics, Llc Improved methods and compositions for the treatment of pemphigus or pemphigoid disease
WO2025137668A1 (en) 2023-12-21 2025-06-26 Constant Therapeutics, Llc Methods and compositions for the treatment of optic neuropathy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5079600A (en) * 1987-03-06 1992-01-07 Schnur Joel M High resolution patterning on solid substrates
JP2945680B2 (ja) * 1988-09-09 1999-09-06 旭硝子株式会社 ペプチド誘導体およびその用途
US5231082A (en) * 1989-05-10 1993-07-27 Monsanto Company Cyclic peptide with anti-metastasis activity
JPH05500504A (ja) * 1989-09-27 1993-02-04 アテナ・ニュウロサイエンスィズ・インコーポレイテッド 細胞付着阻止のための組成物及び使用方法
EP0619841B1 (en) * 1990-10-30 1998-07-08 La Jolla Cancer Research Foundation T-cadherin adhesion molecule
EP0617705B1 (en) * 1991-11-22 1997-09-24 Yeda Research And Development Company, Ltd. Non-peptidic surrogates of the arg-gly-asp sequence and pharmaceutical compositions comprising them
US5646250A (en) 1992-04-17 1997-07-08 Doheny Eye Institute Cadherin polypeptides
AU5669494A (en) 1992-11-17 1994-06-08 Yale University Human homolog of the e-cadherin gene and methods based thereon
US5591432A (en) * 1993-02-17 1997-01-07 Becton, Dickinson And Company Antibody to the neural cell adhesion molecule and methods of use
US5665590A (en) * 1994-07-29 1997-09-09 Systemix, Inc. Method for isolating and directly cloning genes which encode cell-surface and secreted proteins
WO1996040781A1 (en) * 1995-06-07 1996-12-19 Tanabe Seiyaku Co., Ltd. CYCLIC PEPTIDE INHIBITORS OF β1 AND β2 INTEGRIN-MEDIATED ADHESION
GB9517098D0 (en) * 1995-08-21 1995-10-25 Imperial College Receptor
US6169071B1 (en) 1996-07-12 2001-01-02 Mcgill University Compounds and methods for modulating cell adhesion
US6031072A (en) 1996-07-12 2000-02-29 Mcgill University Compounds and methods for modulating cell adhesion
US6551994B1 (en) 1997-04-10 2003-04-22 Mcgill University Compounds and methods for inhibiting the interaction between α-catenin and β-catenin

Also Published As

Publication number Publication date
ES2297861T3 (es) 2008-05-01
EP0937103A2 (en) 1999-08-25
US20020151475A1 (en) 2002-10-17
JP2001500475A (ja) 2001-01-16
AU3332297A (en) 1998-02-09
US6914044B2 (en) 2005-07-05
EP0937103B1 (en) 2007-11-28
WO1998002452A3 (en) 1998-03-05
DE69738326D1 (de) 2008-01-10
US6031072A (en) 2000-02-29
US6326352B1 (en) 2001-12-04
WO1998002452A2 (en) 1998-01-22
CA2259966A1 (en) 1998-01-22
DE69738326T2 (de) 2008-07-03

Similar Documents

Publication Publication Date Title
AU722985B2 (en) Compounds and methods for modulating cell adhesion
US6169071B1 (en) Compounds and methods for modulating cell adhesion
US6310177B1 (en) Compounds and methods for modulating tissue permeability
AU764271B2 (en) Compounds and methods for modulating cadherin-mediated functions
US7122623B2 (en) Compounds and methods for modulating cell adhesion
AU773028B2 (en) Compounds and methods for modulating claudin-mediated functions
US6465427B1 (en) Compounds and methods for modulating cell adhesion
US6346512B1 (en) Compounds and methods for modulating cell adhesion
US6756356B2 (en) Compounds and methods for modulating claudin-mediated functions

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)